259 related articles for article (PubMed ID: 21610153)
21. AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.
Marinov M; Ziogas A; Pardo OE; Tan LT; Dhillon T; Mauri FA; Lane HA; Lemoine NR; Zangemeister-Wittke U; Seckl MJ; Arcaro A
Clin Cancer Res; 2009 Feb; 15(4):1277-87. PubMed ID: 19228731
[TBL] [Abstract][Full Text] [Related]
22. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
23. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
24. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
[TBL] [Abstract][Full Text] [Related]
25. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
[TBL] [Abstract][Full Text] [Related]
26. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
28. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
[TBL] [Abstract][Full Text] [Related]
29. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
[TBL] [Abstract][Full Text] [Related]
30. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
31. Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423.
Kashiyama T; Oda K; Ikeda Y; Shiose Y; Hirota Y; Inaba K; Makii C; Kurikawa R; Miyasaka A; Koso T; Fukuda T; Tanikawa M; Shoji K; Sone K; Arimoto T; Wada-Hiraike O; Kawana K; Nakagawa S; Matsuda K; McCormick F; Aburatani H; Yano T; Osuga Y; Fujii T
PLoS One; 2014; 9(2):e87220. PubMed ID: 24504419
[TBL] [Abstract][Full Text] [Related]
32. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma.
Kapoor V; Zaharieva MM; Das SN; Berger MR
Cancer Lett; 2012 Jun; 319(1):39-48. PubMed ID: 22202640
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide synergizes with everolimus (Rad001) to induce cytotoxicity of ovarian cancer cells through increased autophagy and apoptosis.
Liu N; Tai S; Ding B; Thor RK; Bhuta S; Sun Y; Huang J
Endocr Relat Cancer; 2012 Oct; 19(5):711-23. PubMed ID: 22919067
[TBL] [Abstract][Full Text] [Related]
34. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
[TBL] [Abstract][Full Text] [Related]
35. CWF-145, a novel synthetic quinolone derivative exerts potent antimitotic activity against human prostate cancer: Rapamycin enhances antimitotic drug-induced apoptosis through the inhibition of Akt/mTOR pathway.
Hung CM; Lin YC; Liu LC; Kuo SC; Ho CT; Way TD
Chem Biol Interact; 2016 Dec; 260():1-12. PubMed ID: 27769712
[TBL] [Abstract][Full Text] [Related]
36. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A
Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764
[TBL] [Abstract][Full Text] [Related]
37. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
Márk Á
Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
[TBL] [Abstract][Full Text] [Related]
38. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
39. Xiaoaiping injection enhances paclitaxel efficacy in ovarian cancer via pregnane X receptor and its downstream molecules.
Zhang XQ; Ding YW; Chen JJ; Xiao X; Zhang W; Zhou L; Kong QW; Shi MZ; Yang J; Jiang B; Guo C; Han YL
J Ethnopharmacol; 2020 Oct; 261():113067. PubMed ID: 32505840
[TBL] [Abstract][Full Text] [Related]
40. Differential susceptibility to etoposide in clones derived from a human ovarian cancer cell line.
Balan KV; Sitaras NM; Dimas K; Han Z; Wyche JH; Pantazis P
Chemotherapy; 2006; 52(3):137-46. PubMed ID: 16645270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
